A method and system for the transmission of radiopharmaceutical synthesis data
By analyzing the differences in the changing trends of radiopharmaceutical synthesis data, dividing the sequence into segments and encrypting them using the AES algorithm, the problem of the inability to adjust encryption security and transmission speed in existing technologies was solved, enabling data transmission that can adapt to different reaction stages.
Patent Information
- Application Number
- CN202610392773.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-27
- Publication Date
- 2026-06-23
AI Technical Summary
Existing data encryption algorithms cannot adjust the encryption security and transmission speed requirements according to different reaction stages in the radiopharmaceutical synthesis process, thus failing to meet the storage needs of different types of drug synthesis data.
By analyzing the differences in the changing trends between drug synthesis data, the effects of adjustment distance and data fluctuations are determined. Sequence segments are divided and encrypted using the AES algorithm to achieve data transmission.
It meets the different requirements for encryption and transmission at different reaction stages in the synthesis of radiopharmaceuticals, and solves the problem of adjusting the requirements for encryption security and transmission speed.
Smart Images
Figure CN122268865A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of data transmission technology, and specifically to a method and system for transmitting data during radiopharmaceutical synthesis. Background Technology
[0002] Radiopharmaceuticals are drugs containing radioactive nuclides used for medical diagnosis and treatment. They can be selectively absorbed by specific tissues or organs in the body, and the radiation emitted by the radioactive nuclides can be visualized using specialized display equipment. The synthesis of radiopharmaceuticals involves multiple different types of drug synthesis data at various reaction stages. This data needs to be transmitted and stored after drug production is completed to preserve its integrity and facilitate subsequent drug tracking.
[0003] Before transmitting drug synthesis data, it is necessary to encrypt the data to ensure its security. However, different types of drug synthesis data correspond to different reaction stages in the radiopharmaceutical synthesis process, and the requirements for encryption and subsequent transmission are different. Existing data encryption algorithms cannot meet the requirements of adjusting the encryption security and transmission speed according to the storage needs of drug synthesis data. Summary of the Invention
[0004] This invention provides a method and system for transmitting radiopharmaceutical synthesis data, addressing the problem that different drug synthesis data have varying storage requirements, and the requirements for encryption security and transmission speed cannot be adjusted according to needs. The specific technical solution adopted is as follows: In a first aspect, one embodiment of the present invention provides a method for transmitting data in radiopharmaceutical synthesis, the method comprising the following steps: Collect current and historical radiopharmaceutical synthesis data and data generation time, and construct a drug synthesis data sequence for current and historical radiopharmaceuticals, wherein the drug synthesis data includes purity test results; In the drug synthesis data, any two different data types are designated as the target type and the comparison type, respectively. The rate of change of adjacent time data of the drug synthesis data of the target type is determined. Combining the drug synthesis data and the data generation time, the adjustment distance between the drug synthesis data of the target type and the comparison type is determined. Any data generation time is designated as the target data generation time. Based on the difference between the adjustment distances of all different types of drug synthesis data with adjacent data generation times of the target data generation time, the data fluctuation impact of the target data generation time is determined. Construct single-difference sequences for the drug synthesis data sequences of the current radiopharmaceutical and single-difference sequences. Determine the quality impact of the synthesized drug for a single difference type based on the difference in purity test results between the current radiopharmaceutical drug synthesis data sequences and the single-difference sequence drug synthesis data, and the adjustment distance of the single-difference sequence drug synthesis data. Determine the outlier evaluation value of the current radiopharmaceutical based on the quality impact of all single-difference sequences corresponding to the current radiopharmaceutical drug synthesis data sequence, the data fluctuation impact of the target data generation time, and the adjacent time data change rate of all drug synthesis data at the target data generation time. Divide the current radiopharmaceutical drug synthesis data sequence into sequence segments. Encryption of sequence segments enables the transmission of radiopharmaceutical synthesis data.
[0005] Furthermore, the method for determining the rate of change of adjacent time data for the drug synthesis data of the target type is as follows: The drug synthesis data of the target type that is closest in time to the data generation time of the drug synthesis data of the target type is recorded as the data of the previous moment of the drug synthesis data of the target type. The absolute value of the difference between the drug synthesis data of the target type and the data at the previous time point is recorded as the adjacent time data difference of the drug synthesis data of the target type. The ratio of the difference between adjacent time data to the drug synthesis data of the target type is denoted as the rate of change of adjacent time data of the drug synthesis data of the target type.
[0006] Furthermore, the method for determining the adjustment distance between the drug synthesis data of the target type and the comparison type is as follows: The synthesis data of the target drug are arranged in chronological order of data generation time to obtain the synthesis data sequence of the same type of drug. The DTW distance between the drug synthesis data sequences of the same type in the target type and the comparison type is denoted as the data distribution difference between the drug synthesis data of the target type and the comparison type. The product of the rate of change of adjacent time data of the target type of drug synthesis data and the difference in data distribution between the target type and the comparison type of drug synthesis data is denoted as the matching distance between the target type and the comparison type of drug synthesis data. Replace the values of the matching distances between two different types of drug synthesis data with the values corresponding to the two drug synthesis data in the distance matrix of the DTW algorithm, and then use the DTW algorithm to obtain the adjusted distance between any two different types of drug synthesis data.
[0007] Furthermore, the specific methods for determining the impact of data fluctuations during the target data generation time include: For a first preset threshold number of data generation times centered on the target data generation time, the absolute value of the difference between the adjustment distance of the target type and the comparison type of drug synthesis data at the same data generation time is recorded as the first absolute value of the same data generation time. The sum of the first absolute values of the first preset threshold number of data generation times centered on the target data generation time is recorded as the data fluctuation impact of the target data generation time.
[0008] Furthermore, the specific method for constructing the single-difference sequence of the single-difference type and the drug synthesis data sequence of the current radiopharmaceutical is as follows: A historical radiopharmaceutical synthesis data sequence that differs from the current radiopharmaceutical synthesis data sequence in one category of drug synthesis data value is denoted as a single-category difference sequence of the current radiopharmaceutical synthesis data sequence. The data categories in the single-category difference sequence that differ from the drug synthesis data in the current radiopharmaceutical synthesis data sequence are denoted as a single difference category of the current radiopharmaceutical synthesis data sequence and the single-category difference sequence.
[0009] Furthermore, the specific method for determining the quality impact of synthetic drugs with single-difference categories is as follows: The absolute value of the difference between the current drug synthesis data sequence of radiopharmaceuticals and the purity test results of single-type differential sequences is denoted as the product quality difference of a single differential type. The adjustment distance between the current radiopharmaceutical synthesis data sequence and the single-difference-type synthesis data in the single-difference sequence is denoted as the single-difference-type production condition difference. The product of the product quality difference and the production condition difference for a single-difference type is denoted as the quality impact degree of the synthetic drug for that single-difference type.
[0010] Furthermore, the specific method for determining the outlier evaluation value of the current radiopharmaceutical data includes: The minimum value of the quality impact of the synthesized drug for all single-difference types corresponding to the current radiopharmaceutical drug synthesis data sequence is denoted as the total quality impact value of the current radiopharmaceutical synthesized drug. The product of the data fluctuation impact at the target data generation time and the total impact of the current radiopharmaceutical synthesis drug quality is denoted as the first product of the target data generation time; the sum of the cumulative sum of the rate of change of all drug synthesis data at adjacent time points at the target data generation time and the sum of the first product of the target data generation time is denoted as the data outlier at the target data generation time. The normalized sum of the outlier values of all drug synthesis data for the current radiopharmaceutical at the data generation time is denoted as the outlier evaluation value of the current radiopharmaceutical data.
[0011] Furthermore, the specific method for dividing the current radiopharmaceutical synthesis data sequence into sequence segments includes: When the outlier evaluation value of the current radiopharmaceutical data is greater than the evaluation threshold, drug synthesis data of the same data type in the drug synthesis data sequence will be divided into the same sequence segment; When the outlier evaluation value of the current radiopharmaceutical data is less than or equal to the evaluation threshold, the drug synthesis data sequence of the current radiopharmaceutical is directly recorded as a sequence segment.
[0012] Furthermore, the specific methods for encrypting sequence segments to enable the transmission of radiopharmaceutical synthesis data include: The initial value of the iteration length is set to 0, and any sequence segment is denoted as the target sequence segment. The product of 128 and the iteration length is denoted as the second product. The absolute value of the difference between the length of the target sequence segment and the second product is denoted as the first length of the target sequence segment. The sum of the first lengths of all sequence segments is denoted as the first sum of the current radiopharmaceutical. The negative of the first sum of the current radiopharmaceutical is used as the exponent of the exponential function with the natural constant as the base. The value of the exponential function is denoted as the encryption optimization degree of the iteration length. When the encryption priority of the iteration length is less than the priority threshold, the value of the iteration length is incremented by 1, and the encryption priority is re-determined based on the iteration length, the length and number of sequence segments. The re-determined encryption priority is compared with the priority threshold until the encryption priority of the iteration length is greater than or equal to the priority threshold. The value of the iteration length corresponding to the encryption preference degree that is greater than or equal to the preference threshold is denoted as the preferred encryption length; When the length of the sequence segment is less than the preferred encryption length, the sequence segment is padded with random numbers until the length of the sequence segment is equal to the preferred encryption length; when the length of the sequence segment is equal to the preferred encryption length, no processing is performed on the sequence segment; when the length of the sequence segment is greater than the preferred encryption length, the sequence segment is padded with random numbers until the length of the sequence segment is equal to the smallest integer multiple of the preferred encryption length. The completed sequence segment is encrypted using the AES algorithm to obtain ciphertext data. The ciphertext data is then transmitted via network communication, and all ciphertext data is stored in a storage device.
[0013] Secondly, embodiments of the present invention also provide a radiopharmaceutical synthesis data transmission system, including a memory, a processor, and a computer program stored in the memory and running on the processor, wherein the processor executes the computer program to implement the steps of any of the methods described above.
[0014] The beneficial effects of this invention are: This application first analyzes the differences in the changing trends of drug synthesis data among different data types. Then, it determines the adjustment distance between two different data types of drug synthesis data by combining the degree of change of drug synthesis data of the same data type at adjacent data generation times. This adjustment distance avoids the problem of excessively small adjustment distances caused by the close values of two unrelated drug synthesis data types. Next, based on the differences in the adjustment distances between all different types of drug synthesis data at adjacent data generation times of the target data generation time, the impact of data fluctuations at the target data generation time is determined. The greater the data fluctuation impact at the target data generation time, the greater the influence on radiopharmaceutical synthesis at that time. The greater the impact, the better. Furthermore, the influence of drug synthesis data for each data type on the synthesized radiopharmaceutical is analyzed to determine the quality impact of synthesized drugs of a single differential type. The necessity of segmenting the current radiopharmaceutical drug synthesis data into sequence segments is evaluated. Based on the outlier evaluation value of the current radiopharmaceutical data, the current radiopharmaceutical drug synthesis data sequence is divided into sequence segments. Finally, the sequence segments are encrypted to enable the transmission of radiopharmaceutical synthesis data. During transmission, the different requirements for encryption and subsequent transmission at different reaction stages in the radiopharmaceutical synthesis process are met, addressing the problem that different drug synthesis data have different storage needs, and the requirements for encryption security and transmission speed cannot be adjusted according to needs. Attached Figure Description
[0015] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0016] Figure 1 This is a schematic flowchart of a radiopharmaceutical synthesis data transmission method provided in one embodiment of the present invention; Figure 2 This is a flowchart of the matching distance acquisition process provided in one embodiment of the present invention. Detailed Implementation
[0017] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0018] Please see Figure 1The diagram illustrates a flowchart of a radiopharmaceutical synthesis data transmission method according to an embodiment of the present invention, which includes the following steps: Step S001: Collect drug synthesis data and data generation time of current and historical radiopharmaceuticals, and construct a drug synthesis data sequence of current and historical radiopharmaceuticals, wherein the drug synthesis data includes purity test results.
[0019] In the process of radiopharmaceutical synthesis, all synthesis data for the same radiopharmaceutical are extracted.
[0020] Preferably, in one embodiment of this application, the drug synthesis data includes a data identifier, timestamp, operator ID, synthesis batch number, radioactive isotope name, radioactivity before synthesis, radioactivity after synthesis, synthesis efficiency, purity test results, key quality control parameters, total synthesis time, synthesis equipment serial number, and synthesis reaction conditions.
[0021] In this data structure, the data identifier is a unique number or code that identifies the data record, such as RD-2023-04-15-001; the timestamp is used to record the date and time of the radiopharmaceutical synthesis process, such as 2023-04-15, 09:30:00; the operator ID is a unique identifier for the operator performing the synthesis operation, such as OP-0023; the synthesis batch number is a unique identifier for the synthesis batch, such as Batch-12345; the radioisotope name is the name of the radioisotope used, such as fluorine-18; the pre-synthesis radioactivity is the radioisotope activity before the start of radiopharmaceutical synthesis, such as 3.5Ci (Curie); and the post-synthesis radioactivity is the radioisotope activity after the completion of radiopharmaceutical synthesis, such as... For example, 3.2Ci (Curie); Synthesis efficiency is the efficiency of the radiopharmaceutical synthesis process, calculated as the ratio of the activity after synthesis to the activity before synthesis multiplied by 100%, for example, 91.4%; Purity test result is the purity test result of the synthesized radiopharmaceutical, for example, 99.5%; Critical quality control parameters are the key quality control parameters in the synthesis process, such as temperature 37 degrees, pressure 1.5 atm, pH 7.4; Synthesis time is the total time consumed in the radiopharmaceutical synthesis process, for example, 45 minutes; Synthesis equipment serial number: the serial number of the equipment used to synthesize the radiopharmaceutical, for example, Device-Serial-67890; Synthesis reaction conditions are the reaction conditions set in the radiopharmaceutical synthesis process, such as temperature, pressure, and pH.
[0022] The drug synthesis data sequence of the same radiopharmaceutical is obtained by sorting all the drug synthesis data in the order in which the drug synthesis data was generated.
[0023] Since multiple portions of the synthesized radiopharmaceutical exist, it is understandable that each portion of the radiopharmaceutical has a corresponding drug synthesis data sequence. Similarly, it is understandable that each drug synthesis data set has a corresponding data generation time.
[0024] To facilitate differentiation, the radiopharmaceutical produced most recently is designated as the current radiopharmaceutical, and all other radiopharmaceuticals are designated as historical radiopharmaceuticals.
[0025] It should be noted that all drug synthesis data does not include the units corresponding to the data, only the numerical values of the data.
[0026] At this point, the drug synthesis data sequences of current and historical radiopharmaceuticals, as well as the data generation time of all drug synthesis data in the drug synthesis data sequences, have been obtained.
[0027] Step S002: Any two different data types in the drug synthesis data are designated as the target type and the comparison type, respectively. The rate of change of adjacent time data of the drug synthesis data of the target type is determined. Combining the drug synthesis data and the data generation time, the adjustment distance between the drug synthesis data of the target type and the comparison type is determined. Any data generation time is designated as the target data generation time. Based on the difference between the adjustment distances of all different types of drug synthesis data with adjacent data generation times of the target data generation time, the data fluctuation impact of the target data generation time is determined.
[0028] The requirements for storing and transmitting drug synthesis data differ at different reaction stages in the radiopharmaceutical synthesis process. For example, during the monitoring reaction stage, efficient data transmission is crucial; during the raw material preparation stage, accuracy and integrity of the data transmission are paramount. Therefore, it is necessary to segment the current radiopharmaceutical synthesis data sequence into different sequence segments. Different transmission speeds and encryption security levels should be applied to the data contained in each segment to ensure that the data transmission requirements at different reaction stages are met.
[0029] The synthesis data of any one type of drug is denoted as the synthesis data of the target type of drug. This embodiment uses the synthesis data of any one type of drug as an example for illustration. The synthesis data of the target type of drug is arranged in chronological order of data generation time to obtain the synthesis data sequence of the same type of drug for the target type.
[0030] The same method can be used to obtain the synthesis data sequence of any type of drug.
[0031] The DTW distance between the same drug synthesis data sequences of two different types of drug synthesis data is denoted as the data distribution difference between the two different types of drug synthesis data.
[0032] The drug synthesis data of the target type whose data generation time is closest to that of the drug synthesis data of the target type is recorded as the previous time data of the drug synthesis data of the target type. The absolute value of the difference between the drug synthesis data of the target type and the previous time data is recorded as the adjacent time data difference of the drug synthesis data of the target type. The ratio of the adjacent time data difference to the drug synthesis data of the target type is recorded as the adjacent time data change rate of the drug synthesis data of the target type.
[0033] It should be noted that for the drug synthesis data of the target type with the earliest data generation time, there is no previous time data. The rate of change of adjacent time data of the drug synthesis data of the target type with the earliest data generation time is assigned a constant of 0.
[0034] The synthesis data of any other drug class that is different from the target class is denoted as the drug synthesis data of the comparison class.
[0035] The matching distance between the drug synthesis data of the target type and the comparison type is determined based on the rate of change of adjacent time data of the drug synthesis data of the target type and the data distribution difference between the drug synthesis data of the target type and the comparison type.
[0036] The product of the rate of change of adjacent time data of the target type of drug synthesis data and the difference in data distribution between the target type and the comparison type of drug synthesis data is denoted as the matching distance between the target type and the comparison type of drug synthesis data.
[0037] It is understandable that there is a corresponding matching distance between the target drug type and any other drug synthesis data that is different from the target drug type. The matching distance between any two different types of drug synthesis data can be obtained using the same method.
[0038] The flowchart for obtaining the matching distance is as follows: Figure 2 As shown.
[0039] Understandably, the DTW algorithm can be used to obtain the DTW distance between two different types of drug synthesis data. Before calculating the DTW distance using the DTW algorithm, there is a matching relationship and a distance value between every two different types of drug synthesis data. By replacing the corresponding values in the distance matrix of the DTW algorithm with the matching distance values of the two different types of drug synthesis data, the matching relationship and adjusted distance between any two different types of drug synthesis data can be obtained using the DTW algorithm.
[0040] The adjustment distance between two different types of drug synthesis data is obtained by adjusting the distance between the data directly obtained by the DTW algorithm based on the fluctuation of the same type of drug synthesis data at adjacent acquisition times. The greater the fluctuation of the same type of drug synthesis data at adjacent acquisition times, the greater the adjustment distance between the two different types of drug synthesis data.
[0041] Record any data generation time as the target data generation time, and establish a time window for the target data generation time with the target data generation time as the center. The time window includes a first preset threshold number of data generation times.
[0042] It should be noted that when it is not possible to establish a time window containing the first preset threshold number of data generation times with the target data generation time as the center, the first preset threshold number of data generation times that are closest in time to the target data generation time should be selected to establish the time window for the target data generation time.
[0043] The impact of data fluctuations at the target data generation time is determined by the difference in adjustment distances between all different types of drug synthesis data at all data generation times within the time window of the target data generation time.
[0044] For all data generation times within the time window of the target data generation time, the absolute value of the difference between the adjustment distance of the target type and the comparison type of drug synthesis data at the same data generation time is recorded as the first absolute value of the same data generation time. The sum of the first absolute values of all data generation times within the time window of the target data generation time is recorded as the data fluctuation impact of the target data generation time.
[0045] The greater the difference between the adjustment distance of the target type and the comparison type of drug synthesis data at the same data generation time, the greater the difference between the synthesis data of different types of drugs and the more obvious the data fluctuation. At the target data generation time, the impact on radiopharmaceutical synthesis is greater, and the data fluctuation at the target data generation time has a greater impact.
[0046] The same method can be used to obtain the impact of data fluctuations at any data generation time.
[0047] This concludes the analysis of the impact of data fluctuations at all data generation times.
[0048] Step S003: Construct single-type differential sequences for the drug synthesis data sequence of the current radiopharmaceutical and single-type differential sequences. Determine the quality impact of the synthesized drug for the single-type differential sequence based on the difference in purity test results between the drug synthesis data sequence of the current radiopharmaceutical and the single-type differential sequence, and the adjustment distance of the drug synthesis data for the single-type differential sequence. Determine the outlier evaluation value of the current radiopharmaceutical based on the quality impact of all single-type differential sequences corresponding to the drug synthesis data sequence of the current radiopharmaceutical, the data fluctuation impact of the target data generation time, and the adjacent time data change rate of all drug synthesis data at the target data generation time. Divide the drug synthesis data sequence of the current radiopharmaceutical into sequence segments.
[0049] Select historical radiopharmaceutical synthesis data sequences that differ from the current radiopharmaceutical synthesis data sequences in only one category. These selected historical radiopharmaceutical synthesis data sequences are designated as single-category difference sequences of the current radiopharmaceutical synthesis data sequences. The data categories in the single-category difference sequences that differ from the drug synthesis data in the current radiopharmaceutical synthesis data sequences are designated as single difference categories of the current radiopharmaceutical synthesis data sequences and single-category difference sequences.
[0050] It is understood that there are multiple types of drug synthesis data. In this embodiment, the types of drug synthesis data include data identifier, timestamp, operator ID, synthesis batch number, radioactive isotope name, radioactivity before synthesis, radioactivity after synthesis, synthesis efficiency, purity test results, key quality control parameters, total synthesis time, synthesis equipment serial number, and synthesis reaction conditions. Therefore, for the current drug synthesis data sequence of radiopharmaceuticals, each single difference type has a corresponding single-type difference sequence. When the single difference types are different, the corresponding single-type difference sequences will differ.
[0051] Based on the differences in purity test results between current radiopharmaceutical synthesis data sequences and single-type differential sequence synthesis data, and the adjustment distance of single-type differential synthesis data, the quality impact of single-type differential synthesized drugs is determined.
[0052] The absolute value of the difference between the current radiopharmaceutical synthesis data sequence and the purity test results of the single-difference sequence is denoted as the product quality difference of the single-difference type; the adjustment distance between the current radiopharmaceutical synthesis data sequence and the single-difference type drug synthesis data in the single-difference sequence is denoted as the production condition difference of the single-difference type; and the product of the product quality difference of the single-difference type and the production condition difference is denoted as the quality impact degree of the synthesized drug of the single-difference type.
[0053] The greater the difference between the purity test results of the current radiopharmaceutical synthesis data sequence and the single-difference sequence, and the greater the adjustment distance of the single-difference drug synthesis data, the greater the influence of the single-difference drug synthesis data on the synthesized radiopharmaceutical. In this case, the greater the influence of the single-difference synthesized drug on the quality of the synthesized radiopharmaceutical, and the greater the impact of the single-difference drug synthesis data on the synthesized radiopharmaceutical.
[0054] It is understandable that there are multiple types of drug synthesis data, and there are also multiple single difference types corresponding to the current radiopharmaceutical drug synthesis data sequences, with each single difference type corresponding to a synthetic drug quality impact degree.
[0055] Based on the quality impact of all single-difference synthetic drugs corresponding to the current radiopharmaceutical drug synthesis data sequence, the data fluctuation impact of the target data generation time, and the adjacent time data change rate of all drug synthesis data at the target data generation time, the outlier evaluation value of the current radiopharmaceutical data is determined.
[0056] The minimum value of the quality impact of all single-difference synthetic drugs corresponding to the current radiopharmaceutical synthesis data sequence is denoted as the total quality impact value of the current radiopharmaceutical synthesis. The product of the data fluctuation impact at the target data generation time and the total quality impact value of the current radiopharmaceutical synthesis is denoted as the first product of the target data generation time. The sum of the cumulative change rates of all drug synthesis data at adjacent time points at the target data generation time and the first product of the target data generation time is denoted as the data outlier at the target data generation time. The normalized value of the cumulative sum of the data outliers at the data generation times of all drug synthesis data for the current radiopharmaceutical is denoted as the data outlier evaluation value of the current radiopharmaceutical.
[0057] The outlier evaluation value of current radiopharmaceutical data is used to evaluate the necessity of sequence segmentation of current radiopharmaceutical synthesis data. The larger the outlier evaluation value of current radiopharmaceutical data, the more significant the necessity of sequence segmentation of current radiopharmaceutical synthesis data.
[0058] When the outlier evaluation value of the current radiopharmaceutical data exceeds the evaluation threshold, it is necessary to perform sequence segmentation on the current radiopharmaceutical synthesis data sequence. The current radiopharmaceutical synthesis data sequence is divided into sequence segments according to data type. Drug synthesis data of the same data type in the drug synthesis data sequence are grouped into the same sequence segment, and the number of sequence segments is counted.
[0059] The evaluation threshold is a preset threshold, and in this embodiment, the evaluation threshold is set to 0.8.
[0060] When the outlier evaluation value of the current radiopharmaceutical data is less than or equal to the evaluation threshold, the drug synthesis data sequence of the current radiopharmaceutical is directly recorded as a sequence segment. In this case, the number of sequence segments is 1.
[0061] At this point, the current radiopharmaceutical synthesis data sequence is divided into sequence segments.
[0062] Step S004: Encrypt the sequence segment to enable the transmission of radiopharmaceutical synthesis data.
[0063] After the drug synthesis data sequence of a radiopharmaceutical is divided into sequence segments, the sequence segments need to be used as data blocks in the AES encryption algorithm. Each sequence block is compressed using the AES encryption algorithm. Due to the encryption rules of the AES encryption algorithm, the length of the data block needs to be a multiple of 128. Therefore, it is necessary to determine an appropriate encryption length.
[0064] Set iteration length iteration length The initial value is 0, and the encryption preference is determined based on the iteration length, the length and number of sequence segments.
[0065] Let any sequence segment be denoted as the target sequence segment, let the product of 128 and the iteration length be denoted as the second product, let the absolute value of the difference between the length of the target sequence segment and the second product be denoted as the first length of the target sequence segment, let the sum of the first lengths of all sequence segments be denoted as the first sum of the current radiopharmaceutical, let the negative of the first sum of the current radiopharmaceutical be taken as the exponent of the exponential function with the natural constant as the base, and let the value of the exponential function be denoted as the encryption optimization degree of the iteration length.
[0066] The encryption priority of the iteration length is compared with the priority threshold. When the encryption priority of the iteration length is less than the priority threshold, the value of the iteration length is incremented by 1, and the encryption priority is re-determined based on the iteration length, the length and number of sequence segments. The re-determined encryption priority is compared with the priority threshold until the encryption priority of the iteration length is greater than or equal to the priority threshold.
[0067] In this embodiment, the preferred threshold value is 0.8.
[0068] The iteration length corresponding to the encryption preference degree that is greater than or equal to the preference threshold is denoted as the preferred encryption length.
[0069] When the length of the sequence segment is less than the preferred encryption length, the sequence segment is padded with random numbers until the length of the sequence segment is equal to the preferred encryption length; when the length of the sequence segment is equal to the preferred encryption length, no processing is performed on the sequence segment; when the length of the sequence segment is greater than the preferred encryption length, the sequence segment is padded with random numbers until the length of the sequence segment is equal to the minimum integer multiple of the preferred encryption length.
[0070] The completed sequence segment is encrypted using the AES algorithm to obtain ciphertext data. The ciphertext data is then transmitted via network communication, and all ciphertext data is stored in a storage device.
[0071] This completes the transmission of radiopharmaceutical synthesis data.
[0072] Based on the same inventive concept as the above method, this embodiment of the invention also provides a radiopharmaceutical synthesis data transmission system, including a memory, a processor, and a computer program stored in the memory and running on the processor. When the processor executes the computer program, it implements the steps of any one of the above-described radiopharmaceutical synthesis data transmission methods.
[0073] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A method for transmitting data in the synthesis of radiopharmaceuticals, characterized in that, The method includes the following steps: Collect current and historical radiopharmaceutical synthesis data and data generation time, and construct a drug synthesis data sequence for current and historical radiopharmaceuticals, wherein the drug synthesis data includes purity test results; In the drug synthesis data, any two different data types are designated as the target type and the comparison type, respectively. The rate of change of adjacent time data of the drug synthesis data of the target type is determined. Combining the drug synthesis data and the data generation time, the adjustment distance between the drug synthesis data of the target type and the comparison type is determined. Any data generation time is designated as the target data generation time. Based on the difference between the adjustment distances of all different types of drug synthesis data with adjacent data generation times of the target data generation time, the data fluctuation impact of the target data generation time is determined. Construct single-difference sequences for the drug synthesis data sequences of the current radiopharmaceutical and single-difference sequences. Determine the quality impact of the synthesized drug for a single difference type based on the difference in purity test results between the current radiopharmaceutical drug synthesis data sequences and the single-difference sequence drug synthesis data, and the adjustment distance of the single-difference sequence drug synthesis data. Determine the outlier evaluation value of the current radiopharmaceutical based on the quality impact of all single-difference sequences corresponding to the current radiopharmaceutical drug synthesis data sequence, the data fluctuation impact of the target data generation time, and the adjacent time data change rate of all drug synthesis data at the target data generation time. Divide the current radiopharmaceutical drug synthesis data sequence into sequence segments. Encryption of sequence segments enables the transmission of radiopharmaceutical synthesis data.
2. The method for transmitting data in radiopharmaceutical synthesis according to claim 1, characterized in that, The method for determining the rate of change of adjacent time data for the drug synthesis data of the target type is as follows: The drug synthesis data of the target type that is closest in time to the data generation time of the drug synthesis data of the target type is recorded as the data of the previous moment of the drug synthesis data of the target type. The absolute value of the difference between the drug synthesis data of the target type and the data at the previous time point is recorded as the adjacent time data difference of the drug synthesis data of the target type. The ratio of the difference between adjacent time data to the drug synthesis data of the target type is denoted as the rate of change of adjacent time data of the drug synthesis data of the target type.
3. The method for transmitting data in radiopharmaceutical synthesis according to claim 1, characterized in that, The method for determining the adjustment distance between the drug synthesis data of the target type and the comparison type is as follows: The synthesis data of the target drug are arranged in chronological order of data generation time to obtain the synthesis data sequence of the same type of drug. The DTW distance between the drug synthesis data sequences of the same type in the target type and the comparison type is denoted as the data distribution difference between the drug synthesis data of the target type and the comparison type. The product of the rate of change of adjacent time data of the target type of drug synthesis data and the difference in data distribution between the target type and the comparison type of drug synthesis data is denoted as the matching distance between the target type and the comparison type of drug synthesis data. Replace the values of the matching distances between two different types of drug synthesis data with the values corresponding to the two drug synthesis data in the distance matrix of the DTW algorithm, and then use the DTW algorithm to obtain the adjusted distance between any two different types of drug synthesis data.
4. The method for transmitting data in radiopharmaceutical synthesis according to claim 1, characterized in that, The specific methods for determining the impact of data fluctuations during the target data generation time include: For a first preset threshold number of data generation times centered on the target data generation time, the absolute value of the difference between the adjustment distance of the target type and the comparison type of drug synthesis data at the same data generation time is recorded as the first absolute value of the same data generation time. The sum of the first absolute values of the first preset threshold number of data generation times centered on the target data generation time is recorded as the data fluctuation impact of the target data generation time.
5. The method for transmitting data in radiopharmaceutical synthesis according to claim 1, characterized in that, The specific method for constructing the single-difference sequence of the single-difference type and the drug synthesis data sequence of the current radiopharmaceutical is as follows: A historical radiopharmaceutical synthesis data sequence that differs from the current radiopharmaceutical synthesis data sequence in one category of drug synthesis data value is denoted as a single-category difference sequence of the current radiopharmaceutical synthesis data sequence. The data categories in the single-category difference sequence that differ from the drug synthesis data in the current radiopharmaceutical synthesis data sequence are denoted as a single difference category of the current radiopharmaceutical synthesis data sequence and the single-category difference sequence.
6. The method for transmitting data in radiopharmaceutical synthesis according to claim 1, characterized in that, The specific methods for determining the quality impact of synthetic drugs of a single difference type are as follows: The absolute value of the difference between the current drug synthesis data sequence of radiopharmaceuticals and the purity test results of single-type differential sequences is denoted as the product quality difference of a single differential type. The adjustment distance between the current radiopharmaceutical synthesis data sequence and the single-difference-type synthesis data in the single-difference sequence is denoted as the single-difference-type production condition difference. The product of the product quality difference and the production condition difference for a single-difference type is denoted as the quality impact degree of the synthetic drug for that single-difference type.
7. The method for transmitting data in radiopharmaceutical synthesis according to claim 1, characterized in that, The specific methods for determining the outlier evaluation value of the current radiopharmaceutical data include: The minimum value of the quality impact of the synthesized drug for all single-difference types corresponding to the current radiopharmaceutical drug synthesis data sequence is denoted as the total quality impact value of the current radiopharmaceutical synthesized drug. The product of the data fluctuation impact at the target data generation time and the total impact of the current radiopharmaceutical synthesis drug quality is denoted as the first product of the target data generation time; the sum of the cumulative sum of the rate of change of all drug synthesis data at adjacent time points at the target data generation time and the sum of the first product of the target data generation time is denoted as the data outlier at the target data generation time. The normalized sum of the outlier values of all drug synthesis data for the current radiopharmaceutical at the data generation time is denoted as the outlier evaluation value of the current radiopharmaceutical data.
8. The method for transmitting data in radiopharmaceutical synthesis according to claim 1, characterized in that, The specific method for dividing the current radiopharmaceutical synthesis data sequence into sequence segments includes: When the outlier evaluation value of the current radiopharmaceutical data is greater than the evaluation threshold, drug synthesis data of the same data type in the drug synthesis data sequence will be divided into the same sequence segment; When the outlier evaluation value of the current radiopharmaceutical data is less than or equal to the evaluation threshold, the drug synthesis data sequence of the current radiopharmaceutical is directly recorded as a sequence segment.
9. The method for transmitting data in radiopharmaceutical synthesis according to claim 1, characterized in that, The specific methods for encrypting sequence segments to enable the transmission of radiopharmaceutical synthesis data are as follows: The initial value of the iteration length is set to 0, and any sequence segment is denoted as the target sequence segment. The product of 128 and the iteration length is denoted as the second product. The absolute value of the difference between the length of the target sequence segment and the second product is denoted as the first length of the target sequence segment. The sum of the first lengths of all sequence segments is denoted as the first sum of the current radiopharmaceutical. The negative of the first sum of the current radiopharmaceutical is used as the exponent of the exponential function with the natural constant as the base. The value of the exponential function is denoted as the encryption optimization degree of the iteration length. When the encryption priority of the iteration length is less than the priority threshold, the value of the iteration length is incremented by 1, and the encryption priority is re-determined based on the iteration length, the length and number of sequence segments. The re-determined encryption priority is compared with the priority threshold until the encryption priority of the iteration length is greater than or equal to the priority threshold. The value of the iteration length corresponding to the encryption preference degree that is greater than or equal to the preference threshold is denoted as the preferred encryption length; When the length of the sequence segment is less than the preferred encryption length, the sequence segment is padded with random numbers until the length of the sequence segment is equal to the preferred encryption length; when the length of the sequence segment is equal to the preferred encryption length, no processing is performed on the sequence segment; when the length of the sequence segment is greater than the preferred encryption length, the sequence segment is padded with random numbers until the length of the sequence segment is equal to the smallest integer multiple of the preferred encryption length. The completed sequence segment is encrypted using the AES algorithm to obtain ciphertext data. The ciphertext data is then transmitted via network communication, and all ciphertext data is stored in a storage device.
10. A radiopharmaceutical synthesis data transmission system, comprising a memory, a processor, and a computer program stored in the memory and running on the processor, characterized in that, When the processor executes the computer program, it implements the steps of the method as claimed in any one of claims 1-9.